Articles By Jack Cush, MD
The RheumNow Week in Review – 24 February 2017
Dr. Jack Cush reviews highlights from the past week on RheumNow.com:
Read Article
Higher Hip and Knee Replacement Revision Rates in Younger Patients
Joint arthroplasty has grown into a billion dollar industry worldwide. However, optimal timing and the success of total joint replacements in younger patient groups has not been well studied.
Read Article
Sirukumab Effective in Rheumatoid Arthritis
Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 (IL-6) and is being developed for use in rheumatoid arthritis (RA) and other inflammatory diseases.
Read Article
Quarter of Patients Claim Diet Influences Their Rheumatoid Arthritis
Patients often characterize certain foods as “inflammatory” or “anti-inflammatory” as they combat their arthritis.
Read Article
Abatacept Efficacy Giant Cell Arteritis
This appears to be the year for biologic treatments in giant cell artertis (GCA).
Read Article
Biosimilar Reports – February 2017
Biosimilar reports is an ongoing series dedicated to advances, discussions and developments in biosimilar agents intended for use by rheumatologists. Many of these items were compiled from news sources, journal articles and regulatory documents and are cited and linked within each section.
Read Article
The RheumNow Week in Review – 17 February 2017
Dr. Jack Cush reviews this week's news and information from the 2017 RWCS meeting in Maui.
Read Article
BEAM Study: Baricitinib Beats Placebo and Adalimumab in Rheumatoid Arthritis
Baricitinib is a novel inhibitor of Janus kinases JAK1 and JAK2 that has been extensively studied in rheumatoid arthritis (RA). Baricitinib (AKA Oluminant) was recently approved by the EMA for use in Europe at a once daily dose of 4 mg per day.
Read Article
Valeants Brodalumab FDA Approved for Psoriasis
FDA has approvesd the IL-17 targeted therapy Siliq (brodalumab) for moderate-severe plaque psoriasis.
Read Article
Baricitinib Approved in the EU for Use in Rheumatoid Arthritis
The European Commission has approved Eli Lilly's rheumatoid arthritis drug Olumiant (baricitinib) for use in Europe for RA patients with moderate-to-severe active disease in adults who have not responded one or more disease-modifying antirheumatic drugs.
Read Article
